HCAT — Health Catalyst, Inc.

Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $74.7 million, down from $79.6 million year-over-year.
• Full Year 2025 Revenue: $311.1 million, representing 1% year-over-year growth.
• Adjusted EBITDA (Q4 2025): $13.8 million, up from $7.9 million in Q4 2024.
• Full Year Adjusted EBITDA: $41.4 million, a 59% increase year-over-year.
• Technology Revenue: $51.9 million in Q4, and $208.3 million for the full year, a 7% increase year-over-year.
• Professional Services Revenue: $22.8 million in Q4, down 8% year-over-year.
• Adjusted Gross Margin: 53.5% in Q4 and 51.1% for the full year.
• Net Loss: Increased to $178 million in 2025, primarily due to $110.2 million in impairment charges.

2. Strategic Updates and Business Highlights

• New CEO Ben Albert emphasized a renewed focus on operational efficiency and strategic alignment following a leadership transition.
• The company is tightening its leadership structure and focusing on core capabilities to enhance client value.
• Plans to simplify the commercial narrative and improve client engagement through clearer communication of offerings.
• Acknowledgment of the need to streamline operations and reduce complexity in go-to-market strategies.
• Emphasis on leveraging AI and existing data assets to enhance competitive differentiation.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Guidance: Expected to be between $68 million and $70 million.
• Q1 2026 Adjusted EBITDA Guidance: Expected to be between $7 million and $8 million.
• Full-year guidance for 2026 will be provided no later than the next earnings call in May 2026.
• The company is currently in a strategic review phase, assessing all aspects of the business for future growth and efficiency.

4. Bad News, Challenges, or Points of Concern

• Client Churn and Downselling: Anticipated $12.5 million in ARR churn and $52 million at risk due to ongoing migrations from the DOS to Ignite platform.
• Pressure on Revenue: Expected declines in revenue for Q1 2026 due to reduced TEMS-related revenue and ongoing migration challenges.
• Impairment Charges: Significant goodwill and intangible asset impairment charges impacted net loss, reflecting a decrease in market cap and revised forecasts.
• Operational Complexity: The company acknowledged that operational complexity has hindered client value delivery and is a focus area for improvement.

5. Notable Q&A Insights

• Strategic Review: When asked about the potential for selling the company, CEO Ben Albert indicated that the focus is on positioning the company for long-term success rather than considering a sale.
• Migration Challenges: CFO Jason Alger detailed the impact of the DOS to Ignite migration, highlighting that the data platform infrastructure is under significant pressure, with ongoing negotiations to retain client relationships.
• Market Demand: Albert noted that the healthcare market is under pressure to manage costs and improve clinical quality, which presents opportunities for Health Catalyst's solutions.
• Client Retention: Despite some downselling, the company generally maintains strong relationships with enterprise clients, particularly regarding application offerings.

Overall, Health Catalyst is navigating a transitional phase with a focus on operational efficiency and strategic clarity, while facing challenges related to client churn and revenue pressures.